Bayer is considered a long-term buy despite ongoing litigation and high debt, as recent legal wins and expected settlements reduce risks and may boost cash flow. The pharmaceutical segment faces patent expirations but is supported by strong growth from drugs like Nubeqa and Kerendia, plus upcoming launches. The Crop Sciences division is on track with its five-year plan, aiming for above-market growth and better cash flow by 2029. These factors suggest improving fundamentals and potential stock appreciation over time.
Bayer's turnaround story is presented here with a snapshot of the health sector on Pluang as of Oct 19, 2026, 09:02 WIB. Among 150 priced health-sector US stocks, exactly half rose and half fell today. Notable movers include BNGO at USD 1.25 with a 1-day change of -8.76%, MESO at USD 12.69 down 7.98%, and INCY at USD 102.80 down 7.86%, reflecting diverse investor activity across the sector.
Hayati®, a UK-based technology and vaping brand, partnered with elrow at the Edinburgh Festival to launch the "TURN UP WITH HAYATI®" activation. This collaboration featured a dedicated space with interactive activities, special festival edition produ...
The XRP Ledger is set to implement a bug-fix patch on October 23 that addresses issues in Ripple's proposed uncollateralized lending system, which remains inactive due to insufficient validator votes. The patch, requiring 29 validator approvals, also...
The S&P 500's earnings yield rose to 5.28% as of October 16, 2026, a level historically linked to subsequent market rallies. Analysts expect the S&P 500's earnings per share to grow from $365.70 in 2026 to $492.62 by 2028, indicating strong future ea...
Better Home & Finance shares have dropped about 80% due to weak mortgage demand and a leadership battle. The company reported Q3 revenue of $45 million and an EBITDA loss of $25 million, including $8 million in proxy fight expenses. Its Tinman AI pla...
Microsoft has withdrawn from a major data centre project with Australian-founded AI firm Nscale, citing electricity supply issues at the planned Loughton site in Essex. The project, set to be one of the UK’s largest AI computing hubs, faces delays as...
